Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma

Table 2 Correlation of plasma miR-21 and miR-93 with clinicopathological features of esophageal squamous cell carcinoma patients (mean ± SD)

Category	n	miR-21	t/F	P value	miR-93	t/F	P-value
Gender			0.867	0.387		0.337	0.737
Male	95	6.06 ± 1.61			3.63 ± 1.75
Female	33	5.77 ± 1.78			3.74 ± 1.14
Age (yr)			0.590	0.556		0.704	0.483
≤ 65	54	5.89 ± 1.61			3.57 ± 1.67
> 65	74	6.06±1.61			3.76 ± 1.38
Smoking history			1.108	0.270		1.013	0.313
Yes	52	5.80 ± 1.47			3.53 ± 1.70
No	76	6.12 ± 1.69			3.80 ± 1.31
History of alcoholism			1.694	0.093		1.286	0.201
Yes	60	5.73 ± 1.54			3.49 ± 1.46
No	68	6.21 ± 1.65			3.83 ± 1.52
T stage			6.078	< 0.001b		6.489	< 0.001d
T2/T3	98	5.57 ± 1.47			3.27 ± 1.31
T4	30	7.37 ± 1.24			5.03 ± 1.27
N stage			4.503	< 0.001b		6.363	< 0.001d
N0	34	5.00 ± 1.28			2.46 ± 1.21
N1	94	6.35 ± 1.57			4.12 ± 1.34
M stage			6.111	< 0.001b		6.315	< 0.001d
M0	100	5.58 ± 1.45			3.30 ± 1.30
M1	28	7.44 ± 1.28			5.06 ± 1.34
Tumor site			0.219	0.804		0.404	0.669
Upper 1/3 of thoracic part	44	6.10 ± 1.46			3.52 ± 1.45
Middle 1/3 of thoracic part	59	5.89 ± 1.69			3.78 ± 1.37
Lower 1/3 of thoracic part	25	6.02 ± 1.70			3.75 ± 1.88
Pathological differentiation			4.379	< 0.001b		1.371	0.172
Medium/high differentiation	47	5.16 ± 1.38			3.09 ± 1.42
Low differentiation	81	6.43 ± 1.61			3.92 ± 1.50
Tumor length (cm)			0.684	0.495		1.219	0.225
≤ 5	30	5.81 ± 1.55			3.39 ± 1.54
> 5	98	6.04 ± 1.63			3.77 ± 1.48

^bP < 0.01 vs control group;

^dP < 0.01 vs esophageal squamous cell carcinoma patients.